Ultragenyx gains rare disease approval, voucher

FDA approved Crysvita burosumab-twza (KRN23, UX023) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and partner Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat X-linked hypophosphatemia in patients aged one year and older. FDA said Crysvita is the first drug approved in the U.S. for the indication.

With the approval, Ultragenyx received a rare pediatric disease Priority Review voucher. On a conference call Tuesday, CFO and EVP Shalini Sharp said Ultragenyx plans to sell the voucher and share the proceeds equally with Kyowa...